497 related articles for article (PubMed ID: 26243012)
41. Gastrointestinal stromal tumors (GISTs): CD117, DOG-1 and PKCθ expression. Is there any advantage in using several markers?
Ríos-Moreno MJ; Jaramillo S; Pereira Gallardo S; Vallejo A; Mora M; García-Escudero A; Amérigo J; González-Cámpora R
Pathol Res Pract; 2012 Feb; 208(2):74-81. PubMed ID: 22197035
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic relevance of overexpressions of PKC-θ and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases.
Kim KH; Nelson SD; Kim DH; Choi KU; Kim SJ; Min KW; Jang KS; Paik SS; Oh YH; Chae SW; Sohn JH; Kim HJ; Cho YK; Kim BI; Park DI; Sohn CI; Oh S; Choi SH; Choi YJ; Woo HY; Park YL; Park SJ; Lee SH; Ryu S; DO SI; Kang G; Kim K; Cho YH; Pyo JS
Anticancer Res; 2012 Mar; 32(3):923-37. PubMed ID: 22399613
[TBL] [Abstract][Full Text] [Related]
43. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.
Haller F; Gunawan B; von Heydebreck A; Schwager S; Schulten HJ; Wolf-Salgó J; Langer C; Ramadori G; Sültmann H; Füzesi L
Clin Cancer Res; 2005 Sep; 11(18):6589-97. PubMed ID: 16166437
[TBL] [Abstract][Full Text] [Related]
44. Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations.
Rizzo FM; Palmirotta R; Marzullo A; Resta N; Cives M; Tucci M; Silvestris F
BMC Cancer; 2016 Feb; 16():87. PubMed ID: 26867653
[TBL] [Abstract][Full Text] [Related]
45. Gastrointestinal tract spindle cell tumors with interstitial cells of Cajal: Prevalence excluding gastrointestinal stromal tumors.
Lee SJ; Hwang CS; Kim A; Kim K; Choi KU
Oncol Lett; 2016 Aug; 12(2):1287-1292. PubMed ID: 27446428
[TBL] [Abstract][Full Text] [Related]
46. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.
Debiec-Rychter M; Wasag B; Stul M; De Wever I; Van Oosterom A; Hagemeijer A; Sciot R
J Pathol; 2004 Apr; 202(4):430-8. PubMed ID: 15095270
[TBL] [Abstract][Full Text] [Related]
47. A smooth muscle-derived, Braf-driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell-of-origin.
Kondo J; Huh WJ; Franklin JL; Heinrich MC; Rubin BP; Coffey RJ
J Pathol; 2020 Dec; 252(4):441-450. PubMed ID: 32944951
[TBL] [Abstract][Full Text] [Related]
48. Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors.
Yun S; Kim WK; Kwon Y; Jang M; Bauer S; Kim H
Int J Cancer; 2018 May; 142(10):2080-2093. PubMed ID: 29277888
[TBL] [Abstract][Full Text] [Related]
49. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract.
Rossi G; Valli R; Bertolini F; Marchioni A; Cavazza A; Mucciarini C; Migaldi M; Federico M; Trentini GP; Sgambato A
Histopathology; 2005 May; 46(5):522-31. PubMed ID: 15842634
[TBL] [Abstract][Full Text] [Related]
50. Gastrointestinal stromal tumors: differential diagnosis.
Dow N; Giblen G; Sobin LH; Miettinen M
Semin Diagn Pathol; 2006 May; 23(2):111-9. PubMed ID: 17193824
[TBL] [Abstract][Full Text] [Related]
51. Differential Expression of
Yuan J; Kihara T; Kimura N; Hashikura Y; Ohkouchi M; Isozaki K; Takahashi T; Nishida T; Ito A; Hirota S
Pathol Oncol Res; 2021; 27():602008. PubMed ID: 34257559
[TBL] [Abstract][Full Text] [Related]
52. Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism.
Théou-Anton N; Tabone S; Brouty-Boyé D; Saffroy R; Ronnstrand L; Lemoine A; Emile JF
Br J Cancer; 2006 Apr; 94(8):1180-5. PubMed ID: 16570044
[TBL] [Abstract][Full Text] [Related]
53. MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.
Gits CM; van Kuijk PF; Jonkers MB; Boersma AW; van Ijcken WF; Wozniak A; Sciot R; Rutkowski P; Schöffski P; Taguchi T; Mathijssen RH; Verweij J; Sleijfer S; Debiec-Rychter M; Wiemer EA
Br J Cancer; 2013 Sep; 109(6):1625-35. PubMed ID: 23969726
[TBL] [Abstract][Full Text] [Related]
54. Is DOG1 Immunoreactivity Specific to Gastrointestinal Stromal Tumor?
Swalchick W; Shamekh R; Bui MM
Cancer Control; 2015 Oct; 22(4):498-504. PubMed ID: 26678977
[TBL] [Abstract][Full Text] [Related]
55. c-KIT mutation analysis for diagnosis of gastrointestinal stromal tumors in fine needle aspiration specimens.
Willmore-Payne C; Layfield LJ; Holden JA
Cancer; 2005 Jun; 105(3):165-70. PubMed ID: 15822120
[TBL] [Abstract][Full Text] [Related]
56. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.
Arne G; Kristiansson E; Nerman O; Kindblom LG; Ahlman H; Nilsson B; Nilsson O
Int J Cancer; 2011 Sep; 129(5):1149-61. PubMed ID: 21064103
[TBL] [Abstract][Full Text] [Related]
57. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
Zheng S; Chen LR; Wang HJ; Chen SZ
Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
[TBL] [Abstract][Full Text] [Related]
58. Gastrointestinal Kaposi's sarcoma: CD117 expression and the potential for misdiagnosis as gastrointestinal stromal tumour.
Parfitt JR; Rodriguez-Justo M; Feakins R; Novelli MR
Histopathology; 2008 Jun; 52(7):816-23. PubMed ID: 18494611
[TBL] [Abstract][Full Text] [Related]
59. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
[TBL] [Abstract][Full Text] [Related]
60. Targeting ETV1 in gastrointestinal stromal tumors: tripping the circuit breaker in GIST?
Duensing A
Cancer Discov; 2015 Mar; 5(3):231-3. PubMed ID: 25749973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
